INTERLINK COE Networks & Programs

Exciting News in Immunotherapy! The FDA has just approved Lymphir™ by Citius Pharmaceuticals.  LYMPHIRTM (Denileukin Diftitox-cxdl, E7777), is a purified reformulation of denileukin diftitox, a previously FDA-approved cancer immunotherapy for the treatment of persistent or recurrent cutaneous T-cell lymphoma (CTCL), a rare form of non-Hodgkin lymphoma. Improvements to the original formulation resulted in a therapy that maintains the same amino acid sequence but features greater purity and bioactivity and has been approved for use with relapsed or refractory cutaneous T-cell lymphoma (R/R CTCL). The approval is based on a robust multicenter study, showing a 36.2% overall response rate with significant skin disease reduction. LYMPHIR is the only CTCL therapy that targets the IL-2 receptor, and it’s expected to be available within the next five months. Citius plans to further explore the potential of LYMPHIRTM to treat larger patient populations with additional indications in peripheral T-cell lymphoma (PTCL) and immuno-oncology. LYMPHIRTM has been granted orphan drug designation (ODD) by the FDA for the treatment of CTCL and PTCL   At Symphony Benefits Solution, we are committed to helping your organization navigate the complexities and costs of innovative treatments like this. Reach out to us at Sales@thesymphonyprogram to learn how we can support your gene and cell therapy strategies.

Join us on August 22nd, 2024, from 8:30 - 9:30 am PT for an insightful and exclusive Premier Medical Round Table sponsored by INTERLINK and The Symphony Program, entitled "From Science to Solutions: Gene and Cell Therapy in Today’s Healthcare Landscape." Led by Dr. Carolina Escobar, Symphony's Medical Director of Gene and Cell Therapy, and Kris Atkins, RN, CCM, Executive Vice President, Strategy & Innovation The field of Gene and Cell Therapy is evolving rapidly, with new treatments and innovative applications creating complexities for risk-bearing entities. We will discuss recent and upcoming therapy approvals in this dynamic space. Learn from experts about how these therapies will impact patient populations, understand the pricing mechanisms driving increasing costs, and discover strategies to manage expenses while maintaining access for eligible members. Reach out to your account managers today at [email protected] to discover how you can become eligible to join this premier learning event! Don't miss this opportunity to deepen your understanding and contribute to the advancement of Gene and Cell Therapy! #GeneTherapy #CellTherapy #MedicalInnovation #INTERLINK #PremierMedicalRoundTable

At CancerCARE for Life, we're focused on innovation by developing a new solution to support policyholders in implementing cancer prevention strategies and navigating the complexities of a cancer diagnosis. Message me if you have any questions. #CancerPrevention #HealthcareInnovation Heidi Scarbrough Julaine Novak

INTERLINK is thrilled to be attending the Health Care Administrators Association (HCAA) TPA Summit from July 15-17! We look forward to reconnecting with our current TPA partners in person AND meeting new ones. Hope to see you there! #INTERLINK #TPASUMMIT #HCAA

INTERLINK® COE Networks & Programs (INTERLINK) is thrilled to announce our partnership and collaboration with Renalogic as the comprehensive CKD/ESRD/Dialysis management provider in our SYMPHONY Benefits Solution (SYMPHONY) program. SYMPHONY offers plans for a fully integrated COE/local care program for transplants, cancer, CKD/ESRD/Dialysis, and gene and cellular therapies. This collaboration with Renalogic marks a significant milestone in our mission to provide top-tier healthcare solutions, ensuring the best outcomes for our members. Together, we are dedicated to delivering innovative, high-quality care that meets patients' diverse needs and transforms their lives. Read the full announcement here: https://lnkd.in/gZe84FpM #HealthcareInnovation #CKD #ESRD #Dialysis #Transplants #CancerCare #GeneTherapy #CellularTherapy #IntegratedCare #Collaboration #SYMPHONYProgram #Interlink #Renalogic

Significant Advancement in DMD Treatment by Sarepta Therapeutics! While Pfizer's Phase 3 CIFFREO trial for DMD therapy faced setbacks, last Thursday marked a positive shift with Sarepta's ELEVIDYS label receiving FDA approval, expanding treatment options significantly.  Previously, only DMD boys between aged 4 and 5 were FDA approved to receive the therapy, and now, all young DMD boys and men aged 4 and above will have access per the FDA expansion. In addition, previously, there were strict ambulatory restrictions whereby if the child required assistance with ambulation, they were excluded from having access, whereby, now, this milestone FDA expansion includes full approval for non-wheelchair-dependent patients and accelerated approval for those who are wheelchair-dependent. Despite initial challenges, secondary clinical trial results demonstrating improved motor functions supported this decision, bringing renewed hope to families affected by this devastating disease. We anticipate many DMD boys who were denied access over the past year, may now meet guidelines for access to this potentially life-changing treatment option per the FDA expansion. Symphony Benefit Solutions is staying on top of developing stories like this in the gene and cell therapy arena. We are excited for the 7/1 launch of our fully integrated program, which will tackle high-cost gene and cell therapy treatments while remaining at the forefront of this rapidly changing environment. Reach out to us to learn more about how Symphony Benefits Solution can help at [email protected] This development highlights the continued progress and breakthroughs in the fight against DMD.  #DMD #GeneTherapy #SareptaTherapeutics #FDAApproval #MedicalBreakthrough #SymphonyBenefitSolutions

University Health is honored to receive this distinguished “Chairman’s Award” recognition for the second consecutive year in 2024. This accolade underscores the shared commitment that we and our partner, UT Health San Antonio, have to setting a standard of excellence in delivering high quality and compassionate healthcare. We deeply value and appreciate our long-standing relationship with INTERLINK COE Networks & Programs. Learn more in the post below.

Did you know? June is National Cancer Survivor Month. - 69% of survivors have lived 5+ years since their diagnosis. - 47% of survivors have lived 10+ years. - 18% of survivors have lived 20+ years. - Over the next decade, the number of people who have lived 5 or more years after their cancer diagnosis is projected to increase approximately 30%, At CancerCARE, we have been privileged to contribute to the positive outcomes of cancer survivors. We honor those who have faced cancer, defied the odds, and emerged as survivors as well as support all of those who are still fighting the disease. Source: American Cancer Society

The recent failure of Pfizer's late-stage trial for Duchenne muscular dystrophy (DMD) gene therapy marks a significant setback for patients but opens the door for competitors like Sarepta Therapeutics. Pfizer’s gene therapy did not improve motor function in young boys and follows a similar setback for Sarepta’s Elevidys. Despite this, Sarepta remains optimistic, citing positive secondary outcomes and ongoing FDA support. As the biotech landscape evolves, Symphony Benefits Solution is positioned to be a steadfast resource in the gene and cell therapy space, offering the latest insights and support for advancements in these critical therapies. Stay informed with Symphony Benefits Solution for all your gene therapy updates and needs. https://lnkd.in/gr-fpZM4

Please connect with the [email protected] if you’d like more information or would like to get a patient set up with a contract 😊